Zhen Li

This paper develops a chemical genetic strategy to manipulate proteoglycan glycan attachment sites in mammalian cells using modified xylosyltransferases.

ZMS-6659, a Polθ helicase inhibitor, shows anti-tumor activity as monotherapy and synergizes with PARP inhibitors and topoisomerase inhibitors in HR-deficient and HR-proficient models.

The paper introduces BOCTAG, a method to label glycoproteins in specific cell types within mixed cultures, enabling analysis of cell-specific glycosylation.

This paper introduces GalNAzMe, a monosaccharide probe that selectively labels O-GalNAc glycosylation in living cells, enabling detailed study of this cancer-relevant modification.

The paper introduces a method to chemically tag glycans in living cells using engineered glycosyltransferases to study glycan structure and biosynthesis.